百龙创园 20260227 摘要 2025 年膳食纤维总销量超 4.8 万吨，其中聚葡萄糖约 2.1 万吨，抗性 糊精约 2.7 万吨。抗性糊精销量同比增长接近 50%，聚葡萄糖因产能受 限同比下降约 20%。产品结构调整是聚葡萄糖销量下滑主因，并非需求 端走弱。 2025 年阿洛酮糖成交量略高于 1 万吨，同比增长不到 30%，单价同比 下降 10%-20%，主要受上游原料价格影响。但受益于新产线投用和原 料向上游延伸，阿洛酮糖毛利率仍提升不到 10 个百分点。 阿洛酮糖相关酶制剂已获批，产品预计 3 月底前落地。预计 2026 年对 收入和利润有贡献，但具体规模不确定。饮品端或率先导入阿洛酮糖， 因国内无糖饮品市场体量更大，且易实现不含糖。 公司预计阿洛酮糖销量中期增速可维持在 20%-30%甚至更高。当前全 球用量约 3 万吨，未来市场空间大。价格是主要制约因素，需健康意识 提升、下游厂商推动和消费者教育。 新增 2-3 万吨膳食纤维产能项目已进入调试投产阶段，预计二季度开始 贡献收入和利润，四季度左右可能满产。产品结构将根据市场需求决定， 若抗性糊精需求增长快，其增速可能显著快于聚葡萄糖。 Q&A 外 ...

还有6天就到除夕啦！ 教你3招，让你健康吃糖 ↓↓↓ 01 今天是腊月二十三 也是北方小年 "二十三，糖瓜粘" 甜甜的糖果总是令人无法抗拒 一不小心就吃多了～ 但你知道吗？糖吃多了 可能会增加癌症等多种疾病风险 糖的危害比你想象中还大 世界卫生组织(WHO)多次发布膳食指南指出，过量摄入添加糖是威胁健康的重要危险因素，会显著增 加肥胖、2型糖尿病、心血管疾病、龋齿等慢性疾病发生风险。 多项流行病学研究表明，高糖饮食人群的全因死亡风险更高，健康寿命会受到明显影响。 02 糖吃多了可能毁全身 增加患癌症风险 甜食与某些癌症虽没有直接关系，但它们却可能是癌症的潜在源头。糖吃得过多，会引起肥胖，而肥胖 是多种癌症的诱因。 增加患心血管疾病风险 长期大量吃糖，过多的糖分会转化成脂肪储存在体内，容易造成肥胖，增加患心血管疾病风险。 增加患糖尿病风险 吃糖过多，不仅会引起肥胖，还会使胰岛素敏感性下降，从而增加患糖尿病风险。60%以上的2型糖尿 病患者，都有超重、肥胖的现象。 增加患龋齿风险 经常吃糖，会为口腔中的细菌提供一个良好繁殖环境，容易引起龋齿和其他口腔疾病。 增加患脂肪肝风险 糖转化成脂肪后，一部分藏在皮下，另一部 ...

Core Viewpoint - Excessive sugar intake poses significant health risks, including obesity, diabetes, cardiovascular diseases, and dental issues, as highlighted by the World Health Organization (WHO) [1][2] Group 1: Health Risks of Excessive Sugar Intake - High sugar consumption is linked to an increased risk of various chronic diseases, including obesity, type 2 diabetes, cardiovascular diseases, and dental cavities [1][4][6] - Epidemiological studies indicate that individuals with high sugar diets have a higher all-cause mortality risk and a noticeable impact on healthy lifespan [2] - Overconsumption of sugar can lead to obesity, which is a known risk factor for several types of cancer [3] - Long-term high sugar intake can result in fat accumulation, increasing the risk of cardiovascular diseases [4] - Excessive sugar can decrease insulin sensitivity, raising the risk of diabetes, with over 60% of type 2 diabetes patients being overweight or obese [5] - Frequent sugar consumption creates a favorable environment for bacteria in the mouth, leading to dental issues [6] - High sugar intake can contribute to fatty liver disease and other organ-related fat accumulation [7][8] - Increased sugar consumption can accelerate skin aging due to chronic inflammation and oxidative stress [9] Group 2: Healthier Sugar Alternatives - Black sugar is recommended in moderation for its health benefits, such as aiding in blood nourishment and alleviating certain health conditions [10][13] - β-glucan, a natural polysaccharide, helps regulate blood sugar and improve cholesterol levels [15][16] - Oligofructose, a soluble dietary fiber, can aid in preventing constipation and improving nutrient absorption [18][19] Group 3: Guidelines for Healthy Sugar Consumption - The recommended daily intake of added sugars should not exceed 50 grams, ideally limited to 25 grams [20] - It is important to be aware of hidden sugars in food products by checking labels, as many items contain significant amounts of added sugars [22] - Cooking methods that involve high sugar content, such as sweet and sour dishes, should be minimized [23] - Increasing physical activity can help offset the caloric intake from sugar [25] - Awareness of low-sugar food standards is essential to ensure health benefits [24]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 28.00 [1]. Core Insights - The company is expected to see a significant acceleration in performance in Q4, driven by high demand and improved capacity utilization. The projected revenue for 2025 is RMB 1.38 billion, representing a year-on-year increase of 19.75%, with net profit expected to reach RMB 370 million, up 48.9% [5][6]. - The company is well-positioned to benefit from the growing demand for functional sugars, with new production capacity expected to come online in 2026, further enhancing revenue growth [7][8]. Financial Projections - Revenue projections for the upcoming years are as follows: - 2024: RMB 1.15 billion (+32.64%) - 2025: RMB 1.38 billion (+19.74%) - 2026: RMB 1.74 billion (+25.99%) - 2027: RMB 2.23 billion (+28.52%) [4]. - Net profit forecasts are: - 2024: RMB 246 million (+27.26%) - 2025: RMB 367 million (+49.45%) - 2026: RMB 471 million (+28.27%) - 2027: RMB 620 million (+31.70%) [4]. - The company’s EPS is projected to increase from RMB 0.58 in 2024 to RMB 1.48 in 2027 [4]. Valuation Metrics - The company’s PE ratio is expected to decrease from 38.44 in 2024 to 15.23 in 2027, indicating improving valuation as earnings grow [4]. - The PB ratio is projected to decline from 5.62 in 2024 to 3.37 in 2027, reflecting a more attractive valuation over time [4]. - The EV/EBITDA ratio is expected to fall from 24.75 in 2024 to 9.79 in 2027, suggesting enhanced operational efficiency and profitability [4].

Core Insights - The company reported a strong performance in the first half of 2025, with revenue of 649 million yuan, a year-on-year increase of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [1] - The core products continue to grow rapidly, with overseas demand remaining strong, particularly in the prebiotic series, dietary fiber series, and health sweeteners [1][3] Financial Performance - In Q2 2025, the company achieved revenue of 336 million yuan, a year-on-year increase of 20.29%, and a net profit of 88 million yuan, up 33.84% year-on-year [1] - The gross profit margin for H1 2025 was 40.54%, an increase of 7.07 percentage points year-on-year, while the net profit margin was 26.15%, up 3.65 percentage points year-on-year [2] - The company’s operating expenses slightly increased, with sales, management, finance, and R&D expense ratios at 3.15%, 2.43%, 0.01%, and 3.56%, respectively [2] Product and Capacity Expansion - The approval of D-allohexose as a new food ingredient in July 2025 marks a new phase for the company in the domestic market, with expected growth from previously developed products [3] - The company has two projects under construction aimed at expanding production capacity, including a smart production facility for functional sugars and a health food raw material factory in Thailand [3] - Upon completion, these projects will significantly increase production capacity, particularly for overseas clients, with expected annual outputs of 11,000 tons of isomaltulose, 12,000 tons of crystalline allohexose, and more [3] Profit Forecast - The company is projected to achieve net profits attributable to shareholders of 366 million yuan, 489 million yuan, and 657 million yuan for the years 2025 to 2027, representing year-on-year growth rates of 49%, 33%, and 34%, respectively [3] - The current stock price corresponds to price-to-earnings ratios of 24X, 18X, and 14X for the years 2025 to 2027, maintaining a "strong buy" rating [3]

Core Viewpoint - The company is experiencing significant growth in revenue and profit due to the increasing demand for dietary fiber and allulose sugar, with new production capacities contributing to this trend [1][3]. Financial Performance - For the first half of 2025, the company expects total revenue of 650 million yuan, a year-on-year increase of 22.29%, and a net profit attributable to shareholders of 171 million yuan, up 42.68% [1]. - In Q2 2025, the company anticipates total revenue of 336 million yuan, reflecting a 20.49% year-on-year growth, and a net profit of 89 million yuan, which is a 35.06% increase [1]. Product Demand and Market Trends - The approval of D-allulose as a new food ingredient in China is expected to drive rapid growth in domestic demand, particularly in the baking sector [2]. - D-allulose has a sweetness level of 70% compared to sucrose and can be used in various food products, enhancing flavor and color through the Maillard reaction [2]. Production Capacity and Expansion - The company has established itself as a leader in the allulose market, having developed and industrialized various forms of allulose since 2014 [3]. - The construction of a new factory in Thailand is underway, which will produce 12,000 tons of crystalline allulose and expand the company's international market presence [3]. Profit Forecast - The company is projected to achieve net profits of 361 million yuan, 474 million yuan, and 647 million yuan for the years 2025, 2026, and 2027, representing year-on-year growth rates of 47%, 31%, and 37% respectively [3].

Core Viewpoint - The company is focusing on high-value core products such as prebiotics, dietary fibers, and sugar-reducing sweeteners, which are expected to drive future growth and profitability [2][3][4]. Product Focus - The company's core products include prebiotics (oligomaltose, fructooligosaccharides, galactooligosaccharides), dietary fibers (polydextrose, resistant dextrin), and sugar-reducing sweeteners (erythritol, crystalline fructose, allulose) [2]. Gross Margin Improvement - The gross margin for the company's core products increased from 9.74% in 2023 to 15.84% in 2024, driven by optimized product structure, reduced consumption, and lower procurement costs [3][4]. - The gross margins for individual core products are as follows: prebiotics increased from 19.34% to 24.60%, dietary fibers from 12.64% to 18.12%, and sugar-reducing sweeteners from 1.26% to 9.09% [4]. Production Strategy - The company is implementing a "small, refined, and flexible" production model to cater to differentiated market demands, focusing on high-value, small-batch orders [6]. - The flexible production plan aims to enhance responsiveness to market needs and build competitive advantages through customized products [6]. New Product Development - The company is expanding its product line with high-value products such as DHA algae oil, lactulose, and HMOs, with production capacity already established for these new products [8]. - Strategic partnerships have been formed to ensure sales of new products, with ongoing projects in trial production stages [8]. Market Impact of Tariffs - Following the EU's imposition of anti-dumping duties on erythritol, the company has capitalized on being the lowest taxed entity, resulting in a 123% year-on-year increase in erythritol sales revenue in Q1 2025 [8]. Capacity Expansion - The company has been a pioneer in the domestic allulose market, with a production capacity exceeding 5,000 tons set to be expanded to 20,000 tons in the future [9]. Financial Performance - In Q1 2025, the company reported a revenue of 685 million yuan, a 24.23% increase year-on-year, and a net profit of 50.36 million yuan, up 117.35% year-on-year [10].

Group 1 - The core business of the company is to provide drug discovery, development, and production services for global pharmaceutical companies, biotechnology firms, and research institutions [1] - The CRO/CDMO segment is the company's core business, consisting of four service modules: chemical CRO, biological CRO, small molecule CDMO, and large molecule CDMO [1] - The company is one of the few domestic leaders with full-process service capabilities in preclinical CRO and CMO, ranking among the top three in the preclinical CRO market in China [1] Group 2 - As of the latest quarterly report for Q3 2024, the company achieved a revenue of 719 million yuan, a year-on-year decrease of 15.09% [1] - The net profit for the same period was -61.67 million yuan, reflecting a year-on-year decline of 96.88% [1] - The company's gross profit margin stands at 19.22% [1] Group 3 - The company's latest market performance shows a closing price of 5.88 yuan, an increase of 1.91%, with a current price-to-book ratio of 2.14 and a total market capitalization of 2.928 billion yuan [1] - A total of 31 institutions hold shares in the company, with a combined holding of 2.0099 million shares valued at 13 million yuan [1]